Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Cardiology referrals are the breakout growth driver. This is a channel management did not initially anticipate, but it is now reshaping the business. </li><li>More than 85% of cardiovascular patients test positive for OSA, and with 2,500+ US cardiology groups, demand for diagnosis and treatment partners is growing.</li><li>Collaboration deals are forming in Florida and Arizona, with the model designed to deliver pre-qualified patients at near-zero acquisition cost, as already demonstrated in Nevada. </li></ul>

Cardiology referrals are the breakout growth driver. This is a channel management did not initially anticipate, but it is now reshaping the business. More than 85% of cardiovascular patients test positive for OSA, and with 2,500+ US cardiology groups, demand for diagnosis and treatment partners is growing.Collaboration deals are forming in Florida and Arizona, with the model designed to deliver pre-qualified patients at near-zero acquisition cost, as already demonstrated in Nevada. 

VVOS: WTR Insights Conference Takeaways - From Proof of Concept to National Rollout as Hurdles Clear

Vivos Therapeutics

VVOS: WTR Insights Conference Takeaways - From Proof of Concept to National Rollout as Hurdles Clear